Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults
Drugs & Aging · 2024
DOI: 10.1007/s40266-024-01107-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs & Aging, 2024. Verfasst von Emily Schehlein und 1 weiteren Autor:innen. Beteiligte Einrichtung: Brighton Vision Center, Brighton, MI, USA. arobin@glaucomaexpert.com. Hauptthemen laut MEDLINE: rho-Associated Kinases, Glaucoma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Glaucoma is a leading cause of irreversible blindness which preferentially affects older individuals. No medications or therapies which are currently in our arsenal actually treat glaucoma itself. We know that intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma. The primary treatments for glaucoma include medications, laser therapies, and surgical therapies. The Rho kinase inhibitors are the newest class of medications currently on the market and in development for topical IOP-lowering therapy. Studies have shown their ability to lower eye pressure individually and in combination with other medications. Their ability to potentially provide neuroprotective effects for disease modification also gives this class exciting potential for glaucoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brighton Vision Center, Brighton, MI, USA. arobin@glaucomaexpert.com.
- University of Michigan, Ann Arbor, MI, USA.
- Johns Hopkins University, Baltimore, MD, USA.
Zitieren
APA
Schehlein, E., & Robin, A. (2024). Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults. Drugs & Aging. https://doi.org/10.1007/s40266-024-01107-y
Vancouver
Schehlein E, Robin A. Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults. Drugs & Aging. 2024. doi:10.1007/s40266-024-01107-y
BibTeX
@article{Schehlein2024,
author = {Schehlein, Emily and Robin, Alan},
title = {Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults},
journal = {Drugs & Aging},
year = {2024},
doi = {10.1007/s40266-024-01107-y}
}
EUVIMED